desmethylofloxacin: structure given in first source; analog of ofloxacin [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 133905 |
| SCHEMBL ID | 2738965 |
| MeSH ID | M0155033 |
| Synonym |
|---|
| desmethylofloxacin |
| 7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-10-(4-methyl-1-piperazinyl)-7-oxo- |
| desmethyl ofloxacin |
| 82419-46-3 |
| DTXSID40231730 |
| SCHEMBL2738965 |
| 8-fluoro-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6h-1-oxa-3a-aza-phenalene-5-carboxylic acid |
| 7-fluoro-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid |
| Excerpt | Reference | Relevance |
|---|---|---|
| " In the young and elderly, ofloxacin is eliminated with a half-life of five to seven hours, independent of dose." | ( Pharmacokinetics of ofloxacin. An overview. Flor, S, 1989) | 0.28 |
| " In 2 patients with chronic renal failure, specific HPLC assay indicated an extended half-life for ofloxacin (approximately 13 hours) and the appearance in serum of low concentrations of both metabolites after 10 hours, persisting until the last blood sample was taken (32 hours)." | ( A preliminary report on the pharmacokinetics of ofloxacin, desmethyl ofloxacin and ofloxacin N-oxide in patients with chronic renal failure. Lovering, AM; MacGowan, AP; Mackay, IG; Reeves, DS; White, LO, 1987) | 0.27 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " The pharmacokinetics of the compound indicate that, except for cases of renal impairment, little or no dosage adjustment is necessary." | ( Pharmacokinetics of ofloxacin. An overview. Flor, S, 1989) | 0.28 |
| " These results confirm that dosage reduction of ofloxacin is required in haemodialysis patients." | ( The pharmacokinetics of ofloxacin, desmethyl ofloxacin and ofloxacin N-oxide in haemodialysis patients with end-stage renal failure. MacGowan, AP; Mackay, IG; Reeves, DS; White, LO, 1988) | 0.27 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (50.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.23) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||